Puma Common Stock Shares Outstanding vs Non Currrent Assets Other Analysis

PBYI Stock  USD 2.94  0.08  2.65%   
Puma Biotechnology financial indicator trend analysis is much more than just breaking down Puma Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Puma Biotechnology is a good investment. Please check the relationship between Puma Biotechnology Common Stock Shares Outstanding and its Non Currrent Assets Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Common Stock Shares Outstanding vs Non Currrent Assets Other

Common Stock Shares Outstanding vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Puma Biotechnology Common Stock Shares Outstanding account and Non Currrent Assets Other. At this time, the significance of the direction appears to have no relationship.
The correlation between Puma Biotechnology's Common Stock Shares Outstanding and Non Currrent Assets Other is 0.05. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Puma Biotechnology, assuming nothing else is changed. The correlation between historical values of Puma Biotechnology's Common Stock Shares Outstanding and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Puma Biotechnology are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Common Stock Shares Outstanding i.e., Puma Biotechnology's Common Stock Shares Outstanding and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.05
Relationship DirectionPositive 
Relationship StrengthInsignificant

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Issuance Of Capital Stock is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Over EBITDA is estimated to increase to 5.10, while Selling General Administrative is projected to decrease to under 65.7 M.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation10.6M8.9M10.2M9.1M
Interest Income160K813K2.4M1.5M

Puma Biotechnology fundamental ratios Correlations

0.170.170.510.47-0.640.450.850.690.89-0.640.74-0.760.590.660.5-0.110.560.640.540.46-0.750.320.610.82-0.02
0.17-0.780.380.4-0.27-0.48-0.28-0.60.56-0.27-0.450.390.23-0.54-0.430.93-0.51-0.590.670.590.390.59-0.65-0.290.14
0.17-0.78-0.56-0.570.060.620.480.71-0.180.060.61-0.590.040.650.42-0.80.580.7-0.2-0.25-0.59-0.040.740.5-0.01
0.510.38-0.560.97-0.44-0.070.330.140.59-0.440.16-0.250.240.110.180.210.060.090.10.1-0.25-0.240.120.31-0.22
0.470.4-0.570.97-0.47-0.090.280.090.56-0.470.12-0.20.220.050.160.230.010.050.10.09-0.2-0.250.060.27-0.25
-0.64-0.270.06-0.44-0.470.16-0.43-0.32-0.631.0-0.40.39-0.4-0.35-0.210.01-0.26-0.31-0.36-0.280.38-0.2-0.26-0.4-0.1
0.45-0.480.62-0.07-0.090.160.770.720.120.160.72-0.750.230.630.56-0.510.580.770.05-0.05-0.74-0.120.670.79-0.11
0.85-0.280.480.330.28-0.430.770.90.54-0.430.91-0.960.520.830.66-0.50.750.910.220.14-0.95-0.040.830.99-0.16
0.69-0.60.710.140.09-0.320.720.90.32-0.320.94-0.90.310.940.72-0.780.840.95-0.05-0.06-0.9-0.170.980.89-0.12
0.890.56-0.180.590.56-0.630.120.540.32-0.630.39-0.420.580.30.180.30.230.230.710.64-0.420.550.260.520.06
-0.64-0.270.06-0.44-0.471.00.16-0.43-0.32-0.63-0.40.39-0.4-0.35-0.210.01-0.26-0.31-0.36-0.280.38-0.2-0.26-0.4-0.1
0.74-0.450.610.160.12-0.40.720.910.940.39-0.4-0.910.340.950.76-0.680.860.950.08-0.01-0.9-0.110.850.910.0
-0.760.39-0.59-0.25-0.20.39-0.75-0.96-0.9-0.420.39-0.91-0.46-0.86-0.670.61-0.77-0.93-0.110.031.00.15-0.87-0.970.17
0.590.230.040.240.22-0.40.230.520.310.58-0.40.34-0.460.220.080.00.20.280.690.67-0.470.40.280.480.1
0.66-0.540.650.110.05-0.350.630.830.940.3-0.350.95-0.860.220.7-0.730.90.93-0.04-0.07-0.86-0.170.880.820.0
0.5-0.430.420.180.16-0.210.560.660.720.18-0.210.76-0.670.080.7-0.580.720.78-0.07-0.15-0.66-0.270.660.66-0.14
-0.110.93-0.80.210.230.01-0.51-0.5-0.780.30.01-0.680.610.0-0.73-0.58-0.66-0.770.510.480.610.52-0.8-0.510.15
0.56-0.510.580.060.01-0.260.580.750.840.23-0.260.86-0.770.20.90.72-0.660.84-0.04-0.08-0.78-0.170.780.73-0.14
0.64-0.590.70.090.05-0.310.770.910.950.23-0.310.95-0.930.280.930.78-0.770.84-0.06-0.13-0.93-0.250.90.91-0.15
0.540.67-0.20.10.1-0.360.050.22-0.050.71-0.360.08-0.110.69-0.04-0.070.51-0.04-0.060.91-0.110.83-0.140.20.38
0.460.59-0.250.10.09-0.28-0.050.14-0.060.64-0.28-0.010.030.67-0.07-0.150.48-0.08-0.130.910.020.8-0.110.070.33
-0.750.39-0.59-0.25-0.20.38-0.74-0.95-0.9-0.420.38-0.91.0-0.47-0.86-0.660.61-0.78-0.93-0.110.020.14-0.87-0.960.17
0.320.59-0.04-0.24-0.25-0.2-0.12-0.04-0.170.55-0.2-0.110.150.4-0.17-0.270.52-0.17-0.250.830.80.14-0.21-0.070.34
0.61-0.650.740.120.06-0.260.670.830.980.26-0.260.85-0.870.280.880.66-0.80.780.9-0.14-0.11-0.87-0.210.82-0.19
0.82-0.290.50.310.27-0.40.790.990.890.52-0.40.91-0.970.480.820.66-0.510.730.910.20.07-0.96-0.070.82-0.16
-0.020.14-0.01-0.22-0.25-0.1-0.11-0.16-0.120.06-0.10.00.170.10.0-0.140.15-0.14-0.150.380.330.170.34-0.19-0.16
Click cells to compare fundamentals

Puma Biotechnology Account Relationship Matchups

Puma Biotechnology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets234.9M244.2M226.6M222.1M230.5M165.1M
Total Stockholder Equity17.5M(6M)(2.4M)21.6M53.4M63.0M
Net Debt60.2M35.7M53.5M38.1M26.9M28.3M
Cash60M85.3M63.1M76.2M84.6M68.5M
Cash And Short Term Investments60M85.3M63.1M76.2M95.9M71.9M
Common Stock Shares Outstanding38.8M39.6M40.6M44.9M47.6M32.7M
Liabilities And Stockholders Equity234.9M244.2M226.6M222.1M230.5M165.1M
Other Stockholder Equity1.3B1.3B1.4B1.4B1.4B762.9M
Total Liab217.4M250.2M229.0M200.5M177.1M108.6M
Total Current Assets166.3M146.1M140.0M134.3M156.2M127.0M
Total Current Liabilities90.8M114.3M109.6M77.5M99.4M56.7M
Retained Earnings(1.3B)(1.3B)(1.4B)(1.4B)(1.3B)(1.3B)
Accounts Payable19.2M12.1M11.2M6.4M6.9M12.3M
Other Current Liab69.0M81.7M91.3M66.9M48.9M44.6M
Other Liab9M32.3M6.4M12.8M14.7M7.6M
Net Tangible Assets(23.0M)(80.1M)(68.6M)21.6M19.4M18.5M
Property Plant And Equipment Net21.8M18.9M15.8M12.5M8.6M8.4M
Non Current Assets Total68.6M98.1M86.6M87.8M74.3M49.8M
Non Currrent Assets Other6.3M5.1M4.7M4.7M4.8M5.1M
Other Assets6.3M5.1M4.7M4.7M1.00.95
Long Term Debt95.0M84.0M97.1M98.3M65.7M54.2M
Retained Earnings Total Equity(1.3B)(1.3B)(1.4B)(1.4B)(1.2B)(1.3B)
Short Term Investments51.6M8.1M19.0M4.9M11.4M10.8M
Non Current Liabilities Total126.6M135.9M119.4M123.0M77.7M68.1M
Capital Surpluse1.3B1.3B1.4B1.4B1.6B952.6M
Inventory3.2M3.5M7.1M4.5M7.1M8.2M
Other Current Assets2.7M23.8M18.3M8.3M4.7M8.4M
Deferred Long Term Liab5.8M868K955K743K854.5K811.7K
Property Plant And Equipment Gross21.8M18.9M22.6M1.1M16.3M8.7M
Accumulated Other Comprehensive Income(12K)62K0.0(2K)(4K)(4.2K)
Intangible Assets40.5M74.1M66.1M70.6M60.9M34.3M
Property Plant Equipment3.3M2.5M15.8M1.1M1.3M1.3M
Net Receivables28.9M25.5M32.5M40.4M48.5M25.3M
Short Long Term Debt Total120.2M121.0M116.6M114.3M111.5M123.2M
Long Term Debt Total151.9M95.0M84.0M97.1M111.7M104.8M
Net Invested Capital112.4M92.4M94.6M119.9M153.1M135.2M
Net Working Capital75.5M31.9M30.4M56.8M56.8M49.8M

Currently Active Assets on Macroaxis

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.417
Earnings Share
0.47
Revenue Per Share
5.045
Quarterly Revenue Growth
0.435
Return On Assets
0.0973
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.